Amgen (NASDAQ:AMGN) Releases FY 2026 Earnings Guidance

04 Feb 2026, 11:22 by Amy Steele · The Cerbat Gem

Amgen (NASDAQ:AMGN – Get Free Report) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided EPS guidance of 21.600-23.000 for the period, compared to the consensus EPS estimate of 22.020. The company issued revenue guidance of $37.0 billion-$38.4 billion, compared to the consensus revenue estimate of $37.0 billion.

Amgen Trading Down 1.8%

AMGN opened at $338.59 on Wednesday. The company has a quick ratio of 0.99, a current ratio of 1.28 and a debt-to-equity ratio of 5.45. Amgen has a 52 week low of $261.43 and a 52 week high of $353.25. The business’s 50 day moving average is $332.76 and its two-hundred day moving average is $310.04. The firm has a market cap of $182.32 billion, a price-to-earnings ratio of 26.17, a price-to-earnings-growth ratio of 3.03 and a beta of 0.46.

Amgen (NASDAQ:AMGN – Get Free Report) last announced its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. Amgen had a net margin of 19.47% and a return on equity of 162.59%. The business had revenue of $9.87 billion during the quarter, compared to analysts’ expectations of $9.46 billion. During the same period in the prior year, the company earned $5.31 earnings per share. The business’s revenue was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, research analysts predict that Amgen will post 20.62 EPS for the current year.

Amgen Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 13th will be paid a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a dividend yield of 3.0%. This is a boost from Amgen’s previous quarterly dividend of $2.38. The ex-dividend date is Friday, February 13th. Amgen’s dividend payout ratio (DPR) is presently 73.57%.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on AMGN shares. DZ Bank increased their price target on shares of Amgen from $335.00 to $364.00 in a report on Monday, November 10th. Cantor Fitzgerald lifted their price objective on Amgen from $305.00 to $315.00 and gave the stock a “neutral” rating in a research report on Thursday, November 6th. TD Cowen reiterated a “buy” rating on shares of Amgen in a report on Wednesday. Scotiabank began coverage on Amgen in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $385.00 price target for the company. Finally, Daiwa Capital Markets upped their price objective on Amgen from $310.00 to $370.00 and gave the company an “outperform” rating in a research report on Tuesday, November 18th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $343.00.

View Our Latest Research Report on AMGN

Insider Buying and Selling

In related news, SVP Rachna Khosla sold 890 shares of the stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $336.24, for a total transaction of $299,253.60. Following the transaction, the senior vice president directly owned 7,082 shares in the company, valued at approximately $2,381,251.68. This represents a 11.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Murdo Gordon sold 6,879 shares of Amgen stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $336.83, for a total value of $2,317,053.57. Following the completion of the sale, the executive vice president owned 41,923 shares of the company’s stock, valued at $14,120,924.09. This trade represents a 14.10% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 10,908 shares of company stock worth $3,674,966. 0.69% of the stock is owned by company insiders.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

Positive Sentiment: Q4 earnings and revenue topped Street estimates — EPS $5.29 vs. $4.76 expected and revenue $9.87B vs. $9.46B; quarter showed year-over-year sales growth that beat expectations, which supports near-term fundamentals. Amgen quarterly results beat Street estimates on higher sales, lower tax rate
Positive Sentiment: Volume and product mix helped lift margins (company cited double‑digit volume boosts and a lower tax rate), supporting cash generation and profitability metrics investors care about. Amgen Logs Higher Fourth-Quarter Revenue on Double-Digit Volume Boost
Positive Sentiment: Management highlighted blockbuster growth for newer products on the earnings call, indicating uptake that can offset legacy product erosion over time. Amgen Inc (AMGN) Q4 2025 Earnings Call Highlights: Blockbuster Growth and Strategic Challenges
Neutral Sentiment: FY‑2026 guidance was reiterated/set to a range (EPS 21.600–23.000; revenue ~$37.0B–38.4B) — the midpoint is close to Wall Street’s view but the wide range leaves execution and model risk. AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS
Neutral Sentiment: Full earnings-call transcripts and highlights point to strategic challenges and execution priorities (product launches, cost/levers) that will determine whether upside from new products is sustainable. Amgen Inc. (AMGN) Q4 2025 Earnings Call Transcript
Negative Sentiment: Citi maintained a Hold and left its $315 price target unchanged — that target sits below recent market levels and signals some analysts see limited near-term upside. Amgen: Solid New-Product Uptake Offset by Legacy Erosion and Execution Risks, Warranting a Hold Rating
Negative Sentiment: Strategic moves such as ending the Rocatinlimab collaboration with Kyowa Kirin are being re‑priced by some investors and analysts, raising near-term valuation/portfolio questions. Assessing Amgen (AMGN) Valuation After Ending Kyowa Kirin Rocatinlimab Collaboration

Hedge Funds Weigh In On Amgen

Hedge funds have recently made changes to their positions in the business. Sittner & Nelson LLC grew its stake in Amgen by 0.4% in the third quarter. Sittner & Nelson LLC now owns 7,276 shares of the medical research company’s stock worth $2,053,000 after purchasing an additional 30 shares in the last quarter. Apexium Financial LP increased its holdings in shares of Amgen by 1.6% in the 3rd quarter. Apexium Financial LP now owns 2,582 shares of the medical research company’s stock valued at $729,000 after acquiring an additional 40 shares during the last quarter. Binnacle Investments Inc raised its position in shares of Amgen by 26.1% during the 3rd quarter. Binnacle Investments Inc now owns 208 shares of the medical research company’s stock valued at $59,000 after acquiring an additional 43 shares in the last quarter. Peloton Wealth Strategists lifted its stake in Amgen by 0.4% during the third quarter. Peloton Wealth Strategists now owns 11,525 shares of the medical research company’s stock worth $3,252,000 after purchasing an additional 47 shares during the last quarter. Finally, CYBER HORNET ETFs LLC boosted its holdings in Amgen by 3.4% in the third quarter. CYBER HORNET ETFs LLC now owns 1,442 shares of the medical research company’s stock worth $407,000 after purchasing an additional 48 shares during the period. Hedge funds and other institutional investors own 76.50% of the company’s stock.

About Amgen

(Get Free Report)

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.